Cardiovascular Disease

Cardiovascular Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Diazepane derivatives and uses thereof
May 25, 2017 - N°20170145023

The present disclosure provides compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) have been found to bind bromodomains and/or bromodomain-containing proteins (e. G., bromo and extra terminal (bet) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e. G., increased activity) of bromodomains and/or bromodomain-containing ...
NEW Dihydropteridinone derivatives and uses thereof
May 25, 2017 - N°20170145013

The present disclosure provides compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) have been found to bind bromodomains and/or bromodomain-containing proteins (e. G., bromo and extra terminal (bet) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e. G., increased activity) of bromodomains and/or bromodomain-containing ...
NEW Modulators of the relaxin receptor 1
May 25, 2017 - N°20170144984

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (i), wherein a, r1, and r2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e. G., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method ...
Cardiovascular Disease Patent Pack
Download 215+ patent application PDFs
Cardiovascular Disease Patent Applications
Download 215+ Cardiovascular Disease-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Cardiovascular Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Organic compositions to treat apoc3-related diseases
Arrowhead Pharmaceuticals, Inc.
May 18, 2017 - N°20170137814

The present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e. G., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.
Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
Affiris Ag
May 18, 2017 - N°20170137509

The present invention provides monoclonal antibodies specific for one or more truncated variants of human osteopontin and vaccines comprising at least one isolated osteopontin peptide, as well methods for manufacturing said antibodies and vaccines. Furthermore, a diagnostic method making use of said antibodies is provided. Said antibodies and vaccines are used in therapy, especially in treatment and/or prevention of ...
Heterocyclic compounds as pi3k-y inhibitors
Affiris Ag
May 11, 2017 - N°20170129899

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Cardiovascular Disease Patent Pack
Download 215+ patent application PDFs
Cardiovascular Disease Patent Applications
Download 215+ Cardiovascular Disease-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Cardiovascular Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
Critical Care Diagnostics, Inc.
May 04, 2017 - N°20170122942

Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular ...
Method of treating hyperlipidemia and atherosclerosis with mir-30c
The Research Foundation For The State University Of New York
May 04, 2017 - N°20170121713

This disclosure provides a novel role for microrna (mir) regulation of lipid metabolism via the mtp pathway, leading to reductions in apob secretion and blood lipid levels. Mir regulation of the mtp pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of mtp expression and activity by mir regulation is identified as a new therapeutic target ...
Ppar modulators
FundaÇao Universidade De BrasÍlia
May 04, 2017 - N°20170121268

The present application relates to amorfrutin analogs and uses as ppar modulators for the treatment of metabolic syndrome, obesity, hyperlipidemia, elevated fasting blood glucose, elevated blood pressure, low hdl cholesterol, type 2 diabetes, cardiovascular disease, a neurodegenerative disease, malaria or irritable bowel syndrome.
Separation material comprising phosphoryl choline derivatives
Pentracor Gmbh
May 04, 2017 - N°20170120163

The present invention provides phosphoryl choline derivatives of general formula (i), which are suitable to be immobilized on a solid support to provide a separation material of general formula (ii), which bind with both high affinity and high specificity to a protein, more specifically to c-reactive protein and anti-phosphoryl choline antibodies. Said separation materials are particularly useful in the extracorporeal ...
Cardio-metabolic and vascular effects of glp-1 metabolites
The Trustees Of The University Of Pennsylvania
May 04, 2017 - N°20170119853

The present invention relates to compositions and methods for treatment and/or prevention of a cardiovascular disease. In one embodiment, the compositions and methods of the invention relate to continuous administration of a glp-1 or a metabolite thereof for the treatment and/or prevention of a cardiovascular disease.
Pharmaceutical compositions for substituted quinazolinones
Resverlogix Corp.
May 04, 2017 - N°20170119767

The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein a-i (apoa-i), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration
Sigma-tau Industrie Farmaceutiche Riunite S.p.a.
May 04, 2017 - N°20170119720

The present invention relates to homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 pufa) and resveratrol for oral administration, in which the resveratrol is solubilized in a solvent system consisting of omega-3 polyunsaturated fatty acids (n-3 pufa), or their alkyl esters, and a ionic emulsifier. The composition according to the present invention can be formulated as food or nutritional supplement ...
Cardiovascular Disease Patent Pack
Download 215+ patent application PDFs
Cardiovascular Disease Patent Applications
Download 215+ Cardiovascular Disease-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Cardiovascular Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Extended release aspirin
New Haven Pharmaceuticals, Inc.
April 27, 2017 - N°20170112858

The present invention is directed to methods of inhibiting platelet aggregation, reducing serum thromboxane b2 levels, reducing systemic or cardiovascular inflammation, treating or preventing cancer and treating or preventing cardiovascular disease by oral administration of compositions containing extended release acetylsalicylic acid (asa) or a combination of extended release asa and immediate release asa.
Extended release aspirin
New Haven Pharmaceuticals, Inc.
April 27, 2017 - N°20170112857

The present invention is directed to methods of inhibiting platelet aggregation, reducing serum thromboxane b2 levels, reducing systemic or cardiovascular inflammation, treating or preventing cancer and treating or preventing cardiovascular disease by oral administration of compositions containing extended release acetylsalicylic acid (asa) or a combination of extended release asa and immediate release asa.
Benzimidazole derivatives as pi3 kinase inhibitors
Glaxosmithkline Llc
April 27, 2017 - N°20170112844

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in ...
Solid formulations containing omega-3 and resveratrol
Sigma-tau Industrie Farmaceutiche Riunite S.p.a.
April 27, 2017 - N°20170112791

The present application relates to invention a solid composition comprising omega-3 polyunsaturated fatty acids (n-3 pufa), or their alkyl esters, and resveratrol, adsorbed on an inert substrate and wherein the recovery of omega-3 is at least 96% after 6 months at 25° c. The composition according to the present invention can be formulated as food supplement or medicament for preventing or treating ...
Activation of amp-protein activated kinase by oxaloacetate compounds
Sigma-tau Industrie Farmaceutiche Riunite S.p.a.
April 20, 2017 - N°20170105954

The present invention relates to oxaloacetate compounds that activate amp-activated protein kinase (ampk), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, alzheimer's disease, and cancer.
Indolin-2-one or pyrrolo-pyridin-2-one derivatives
Sigma-tau Industrie Farmaceutiche Riunite S.p.a.
April 13, 2017 - N°20170101409

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory ...
Composition comprising bio compound for treating cardiovascular disease
Chonnam National University Hospital
April 13, 2017 - N°20170100372

A pharmaceutical composition and a method for preventing or treating a cardiovascular disease are provided. The pharmaceutical composition includes a bio compound ((2′z,3′e)-6-bromoindirubin-3′-oxime) or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition can specifically act on different types of cells constituting heart tissues, that is, can induce the growth ...
System and method for diagnosis and assessment of cardiovascular disease by comparing arterial supply capacity ...
Heartflow, Inc.
April 06, 2017 - N°20170095292

Systems and methods are disclosed for to determining a blood supply and blood demand. One method includes receiving a patient-specific model of vessel geometry of at least a portion of a coronary artery, wherein the model is based on patient-specific image data of at least a portion of a patient's heart having myocardium; determining a coronary blood supply based on ...